BUZZ-Immunovaccine Inc: Ebola vaccine technology succeeds
** Clinical-stage vaccine developer's shares up 25.8 pct at C$1.22 on the Toronto Venture Exchange
** Announces positive results for a vaccine formulated using its DepoVax technology in an Ebola virus challenge study
** All vaccinated cynomolgus monkeys survived the exposure to a lethal dose of the wild type Zaire strain of Ebola virus, believed to be the most lethal, in a preliminary study
** Up to Friday's close, Immunovaccine's stock had more than doubled this year
© Thomson Reuters 2017 All rights reserved.